Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed malignant neoplasm
• •* Not amenable to standard therapy or has failed existing first- and second-line therapies
• •Tumor positive for somatostatin receptors by OctreoScan within the past 4 weeks
• •At least 1 measurable lesion
• •* Lesions that have been previously irradiated must demonstrate progression since radiation
• •* At least 1 measurable somatostatin receptor-positive lesion that has not been irradiated within the past 4 weeks AND has not had full craniospinal radiation within the past 3 months
• •Bone marrow with at least 40% cellularity OR at least 20% cellularity with one million CD34+ stem cells/kg stored
• •No diffuse bone marrow involvement by OctreoScan scintigraphy
• •PATIENT CHARACTERISTICS:
• •Age
• •2 to 25
• •Performance status
• •COG 0-2 OR
• •Karnofsky 60-100% OR
• •Lansky 60-100%
• •Life expectancy
• •2-12 months
• •Hematopoietic
• •See Disease Characteristics
• •Absolute neutrophil count at least 1,000/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic
• •Bilirubin less than 1.5 times normal
• •AST and ALT less than 2.5 times upper limit of normal
• •Renal
• •Creatinine no greater than 1 mg/dL (children less than 5 years of age)
• •Creatinine less than 1.2 mg/dL (children 5 to 10 years of age)
• •Creatinine less than 1.7 mg/dL (children over 10 years of age) AND
• •Glomerular filtration rate at least 80 mL/min/m\^2
• •Cardiovascular
• •Shortening fraction at least 28% by echocardiogram
• •Ejection fraction at least 50% by bi-plane method of echocardiogram
• •No prior congestive heart failure unless ejection fraction at least 40%
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •No symptomatic congestive heart failure
• •Other
• •No other concurrent malignancy
• •No other significant uncontrolled medical, psychiatric, or surgical condition that would preclude study compliance
• •No antibodies to yttrium Y 90-DOTA-tyr3-octreotide or octreotide
• •No prior allergic reactions to compounds of similar chemical or biologic composition to yttrium Y 90-DOTA-tyr3-octreotide
• •No ongoing or active infection
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 6 months after study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• •Endocrine therapy
• •More than 28 days since prior long-acting somatostatin analogues
• •No concurrent somatostatin analogues 12 hours before or 12 hours after study drug administration
• •Concurrent hormonal therapy (other than somatostatin analogue) allowed provided patient received hormonal therapy for at least 2 months and has stable disease or progressive disease
• •Radiotherapy
• •See Disease Characteristics
• •At least 4 weeks since prior radiotherapy
• •No prior radiotherapy to 25% or more of bone marrow
• •No prior external beam radiotherapy to both kidneys (scatter doses of less than 500 cGy to a single kidney or radiation to less than 50% of a single kidney is allowed)
• •Surgery
• •At least 4 weeks since prior surgery
• •Other
• •Recovered from prior therapy
• •At least 4 weeks since prior investigational drugs
• •No other concurrent approved or investigational anti-neoplastic therapies except for bisphosphonates
• •No concurrent combination antiretroviral therapy for HIV-positive patients